Adam's Take Adam Feuerstein STAT Plus: Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug
Biotech Matthew Herper, Adam Feuerstein, and Angus Chen STAT Plus: ASCO Daily Recap: A CAR-T advance, money talk, and tossing the cancer treatment ‘sandwich’
Biotech Angus Chen STAT Plus: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial
Biotech Matthew Herper STAT Plus: Delfi Diagnostics announces key data, study design for its liquid biopsy test
Biotech Matthew Herper STAT Plus: ASCO24: AstraZeneca won cancer’s big meeting — again. Will that help it fulfill its $80 billion ambition?
Pharma Adam Feuerstein, Matthew Herper, and Angus Chen STAT Plus: ASCO Daily Recap: AstraZeneca’s hat trick, a GSK turnaround, and palliative care as telehealth
Health Angus Chen Palliative care for cancer patients is found to be as effective given virtually as in person
Pharma Matthew Herper STAT Plus: AstraZeneca’s Tagrisso greatly slows cancer for some people with stage 3 lung cancer
Biotech Adam Feuerstein STAT Plus: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment
Pharma Andrew Joseph STAT Plus: ASCO 2024: Data put a new shine on GSK blood cancer drug that was pulled from market
Pharma Adam Feuerstein, Matthew Herper, and Angus Chen STAT Plus: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug
Pharma Angus Chen STAT Plus: At ASCO, pharma leaders explain how ‘smart bomb’ drugs became useful against more cancers
Biotech Elaine Chen STAT Plus: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone
Biotech Adam Feuerstein STAT Plus: With expectations rising, Corbus reveals new data on its ADC bladder cancer treatment
Health Angus Chen How can hospitals boost cancer screening rates? Researchers report that an AI helped
The Readout Meghana Keshavan STAT Plus: The surprising outperformance of a new drug against existing competitors, and other biotech updates
Biotech Matthew Herper STAT Plus: For one rare type of lung cancer, Pfizer pill reduces progression by 81%
In the Lab Angus Chen STAT Plus: ASCO preview: a promising solid tumor CAR-T, an AI patient navigator, and improving palliative care
The Readout Meghana Keshavan STAT Plus: More tumult at BIO amid the company’s fourth CEO in four years
Biotech Angus Chen and Jonathan Wosen STAT Plus: FDA advisers endorse Guardant Health’s colon cancer screening test
Biotech Allison DeAngelis STAT Plus: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical
Matt's Take Matthew Herper New data show the HPV vaccine prevents cancer in men, too. Why don’t more people get it?
Biotech Andrew Joseph STAT Plus: At a flashy new research hub, AstraZeneca lays out ambitious growth goals
In the Lab Angus Chen Black Americans’ risk for breast cancer gains clarity in analysis of 40,000 genomes
Adam's Biotech Scorecard Adam Feuerstein STAT Plus: PDS Biotech’s survival benefit is absurdly overstated
Biotech Andrew Joseph STAT Plus: Galapagos, in makeover mode, strikes deal to make CAR-T therapies at blood centers across U.S.